X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
The funding will support the anticipated expenses for DFD-29 (minocycline hydrochloride), being developed for the treatment of rosacea, including an upcoming New Drug Application submission and preparation for its potential commercial launch.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SWK Holdings
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo RM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment November 09, 2023
Details:
DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: HighCape Capital
Deal Size: $26.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 19, 2023
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment September 18, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Minocycline hydrochloride extended-release tablets is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis that is used for used for treatment of moderate to severe acne.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Minocycline Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
Arestin® (minocycline hydrochloride) is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis, in adults with periodontitis.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Arestin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dental and Oral Health Product Name: Arestin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and CLABSIs.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 08, 2023
Details:
Citius intends to use the net proceeds for pre-clinical and clinical development of its product candidates, including Mino-Wrap, a malleable, bio-absorbable film impregnated with minocycline and rifampin used in patients that elect to undergo reconstructive breast surgery.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
Details:
CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The study successfully demonstrated that the systemic exposure of DFD-29 (minocycline, 40 mg) was significantly lower than that of SOLODYN (105 mg). Additionally, the study showed that food did not have a significant effect on the pharmacokinetics of DFD-29.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
DFD-29 (Minocycline 40 mg) demonstrated statistical significance compared to both placebo and doxycycline 40 mg on both co-primary endpoints—proportion of subjects with IGA treatment success and total inflammatory lesion count reduction from baseline to week 16.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Lead Product(s): Minocycline Hydrochloride,EDTA acid,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citius Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
Published Phase 2 clinical data show DFD-29 (minocycline hydrochloride) had approximately double the efficacy compared to Doxycycline capsules 40 mg on reducing total inflammatory lesions and IGA treatment success for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Amzeeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Journey Medical Corporation
Deal Size: $475.0 million Upfront Cash: $20.0 million
Deal Type: Divestment January 13, 2022
Details:
Through this collaboration, the parties will work together to complete the development of DFD-29. Dr. Reddy’s will provide development support including the monitoring of two Phase 3 clinical trials.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2021
Details:
According to the Mino-Lok® Phase 3 study protocol, the DMC is responsible for conducting interim analyses when 40%, 50% and 65% of the total number of anticipated events have been observed.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
Mino-Lok®, the Company's lead product candidate, is an antibiotic lock therapy designed to salvage central venous catheters (CVCs) in patients with catheter related bloodstream infections (CRBSIs) or central line associated blood stream infections (CLABSIs).
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
Citius Pharmaceuticals will discuss the Company's Phase 3 program for its lead product candidate Mino-Lok®, an antibiotic lock solution being developed to treat patients with catheter-related bloodstream infections (CRBSIs).
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2021
Details:
This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: HY02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates including its antibiotic lock solution, Mino-Lok. Mino-Lok contains minocycline with EDTA and ethanol.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $76.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 17, 2021
Details:
Mino-Lok® pivotal trial interim analysis and review by the Data Monitoring Committee (DMC) expected in the second quarter. Halo-Lido IND (second quarter) and Phase 2b protocol to be filed afterwards.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
The meeting provided VYNE with clear direction on the Phase 3 clinical and pharmaceutical development plans for FCD105 and, should the clinical studies meet their objectives, the meeting provided further clarity on preparations required for the anticipated NDA.
Lead Product(s): Minocycline Hydrochloride,Adapalene
Therapeutic Area: Dermatology Product Name: FCD105
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander infections following breast reconstructive surgeries. Some next steps for Mino-Wrap development include designing and executing a large animal study and the clinical plan.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Approved by the U.S. FDA, ZILXI is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins and acne-like inflammatory lesions.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Zilxi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Data Monitoring Committee (DMC) meeting was held to review the data being generated and analyzed in the Mino-Lok phase 3 trial, and to make recommendations to Citius as to any action that may be necessary regarding the study.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
This notice confirms the allowance of additional claims relative to the Company’s BPX-01 and BPX-04 assets including the Company’s method for treating an active dermatological inflammation or infection.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: BPX-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
The Company intends to use the net proceeds from this offering for general corporate purposes, including its Phase 3 clinical Mino-Lok® trial for the treatment of catheter related bloodstream infections, development of Mino-Wrap, and Phase 2b trial of Halo-Lido cream.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2020
Details:
Mino-Wrap is a novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of Investigator’s Global Assessment treatment success and absolute change from baseline in mean inflammatory counts at Week 12.
Lead Product(s): Minocycline Hydrochloride,Adapalene
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Company's plan is designed to be conducted in parallel with the completion of the Phase 3 pivotal trial.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
AMZEEQ® (minocycline) topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients, has been added to the prescription drug formulary of one of the largest payors in the U.S. AMZEEQ.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cutia Therapeutics
Deal Size: $11.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement April 23, 2020
Details:
The article highlights the in vitro efficacy of Mino-Lok against various strains of Candida auris from studies conducted at MD Anderson Cancer Center Labs.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
Details:
Both studies demonstrated statistically significant superiority of FMX103 compared with vehicle in both primary endpoints of absolute inflammatory lesion reduction.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
